Effect of Mitotane on Adrenocortical Carcinoma Survival
Author Information
Author(s): H.R. Haak, J. Hermans, C.J.H. van de Velde, E.G.W.M. Lentjes, B.M. Goslings, G.-J. Fleuren, H.M.J. Krans
Primary Institution: University Hospital Leiden
Hypothesis
Does achieving high serum levels of mitotane improve survival in patients with adrenocortical carcinoma?
Conclusion
Mitotane treatment is effective in improving survival for patients with adrenocortical carcinoma only when high serum levels are maintained.
Supporting Evidence
- Total tumour resection was feasible in 47 patients (49%).
- Patients who underwent total tumour resection survived significantly longer than those who did not.
- Mitotane treatment with high serum levels had an independently favourable influence on patient survival.
- Mitotane treatment resulting in low serum levels was tantamount to not giving mitotane at all.
- Adjuvant mitotane therapy did not influence survival after total resection.
Takeaway
This study shows that patients with a type of cancer called adrenocortical carcinoma live longer if they take a medicine called mitotane and have high levels of it in their blood.
Methodology
Patients were treated with mitotane and followed up for survival analysis, with serum levels monitored to assess treatment efficacy.
Potential Biases
Potential selection bias in treatment and patient demographics.
Limitations
The study is retrospective and lacks randomized controlled trials to confirm findings.
Participant Demographics
Mean age 44.4 years, 56 females and 40 males.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website